Danaher Corporation (DHR)vsIQVIA Holdings Inc (IQV)
DHR
Danaher Corporation
$230.08
+0.94%
HEALTHCARE · Cap: $163.25B
IQV
IQVIA Holdings Inc
$258.44
-3.33%
HEALTHCARE · Cap: $45.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 48% more annual revenue ($25.61B vs $17.31B). DHR leads profitability with a 16.9% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.98. DHR earns a higher WallStSmart Score of 65/100 (B-).
DHR
Strong Buy65
out of 100
Grade: B-
IQV
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DHR.
Margin of Safety
+13.7%
Fair Value
$205.31
Current Price
$258.44
$53.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.1%
Earnings expanding 37.8% YoY
Generating 1.6B in free cash flow
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Operating Margin, EPS Growth. Profitability is solid with margins at 16.9% and operating margin at 21.1%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
DHR profiles as a mature stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.17 — expect wider price swings.
DHR is growing revenue faster at 8.3% — sustainability is the question.
DHR generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (65/100 vs 59/100), backed by strong 16.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?